CRISPR-Cas9 System for of Type 1 Diabetes Treatment

Ziqing Yang

2025

Abstract

Type 1 diabetes (T1D) is one of serious chronic metabolic illnesses, the reason behind is the hyposecretion of pancreatic β cells because of the autoimmune system, and traditional therapy mainly focuses on insulin replacement, which can not reverse the disease process. In recent years, the discovery and rapid development of gene editing technology like the CRISPR/Cas9 system has provided a new idea for the radical treatment of T1D. In this paper, the use of CRISPR/Cas9 technology for T1D treatment is systematically reviewed. First, based on the pathogenesis of T1D, the core links of immune disorder and β cell function loss are described. Secondly, we reviewed the development of CRISPR/Cas9 from a bacterial adaptive immune system to an efficient gene editing tool, and analyzed its targeted DNA cutting and repair mechanism guided by sgRNA. Further, two main application directions of the technique in T1D were discussed: editing immune cells to inhibit autoimmune attack, and inducing stem cells to differentiate into functional β cells or enhancing endogenous β cell regeneration. Current challenges, including off-target effects, low delivery efficiency, and immunogenicity, are analyzed, and some optimization strategies. Finally, we look forward to the future research direction, emphasizing the importance of interdisciplinary research in promoting clinical transformation and providing ideas for future research.

Paper Citation

in Harvard Style

Yang Z. (2025). CRISPR-Cas9 System for of Type 1 Diabetes Treatment. In Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS; ISBN 978-989-758-789-4, SciTePress, pages 218-222. DOI: 10.5220/0014464900004933

in Bibtex Style

@conference{befs25,
author={Ziqing Yang},
title={CRISPR-Cas9 System for of Type 1 Diabetes Treatment},
booktitle={Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS},
year={2025},
pages={218-222},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0014464900004933},
isbn={978-989-758-789-4},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS
TI - CRISPR-Cas9 System for of Type 1 Diabetes Treatment
SN - 978-989-758-789-4
AU - Yang Z.
PY - 2025
SP - 218
EP - 222
DO - 10.5220/0014464900004933
PB - SciTePress